Retatrutide

Retatrutide (development code LY3437943) is a synthetic peptide and the first triple agonist in clinical development to combine activity at the GIP receptor, the GLP-1 receptor, and the glucagon receptor in a single molecule. It is administered as a once-weekly subcutaneous injection. As of May 2026, it is investigational and has not received FDA approval for any indication.

Eli Lilly began the TRIUMPH Phase 3 program in 2023 after Phase 2 data published in the New England Journal of Medicine showed 24.2 percent mean weight loss at 48 weeks (Jastreboff et al., 2023). That number itself was larger than what tirzepatide had produced in SURMOUNT-1 over 72 weeks, which generated immediate analyst expectations that retatrutide would become the next-generation incretin therapy. The TRIUMPH-4 result in late 2025 extended the curve and added a Phase 3 confirmation.

The TRIUMPH program has enrolled more than 5,800 participants across at least eight registrational trials. Indications under study include obesity, type 2 diabetes, obstructive sleep apnea, knee osteoarthritis with obesity, chronic low back pain, metabolic dysfunction-associated steatotic liver disease (MASLD), and cardiovascular outcomes. A New Drug Application is projected for late 2026 or early 2027, with a possible FDA decision in late 2027 if review proceeds on standard timelines.

The Phase 2 Trial

The Phase 2 study (Jastreboff et al., New England Journal of Medicine, 2023) enrolled 338 adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity, excluding type 2 diabetes. Participants were randomized to retatrutide 1 mg, 4 mg, 8 mg, or 12 mg weekly, or placebo, for 48 weeks. Two of the higher-dose groups were further split by titration speed.

Mean body-weight reduction was 24.2 percent at 12 mg, 17.5 percent at 8 mg, 13.9 percent at 4 mg, and 7.2 percent at 1 mg, versus 2.1 percent for placebo. The 12 mg result was the headline figure. It exceeded the SURMOUNT-1 result for tirzepatide 15 mg (22.5 percent at 72 weeks) at a shorter trial duration. The categorical thresholds were also striking. About 36 percent of participants on the 12 mg dose achieved 25 percent or greater weight loss, a threshold that semaglutide and tirzepatide reach only rarely.

A liver-fat substudy of 98 participants with MASLD reported an 86 percent reduction in hepatic fat fraction at 48 weeks on the 12 mg dose, with 93 percent of treated participants reaching normal liver fat (below 5 percent hepatic fat fraction). This is one of the more striking metabolic-organ effects observed in any incretin trial.

The Phase 2 safety profile was dominated by gastrointestinal events, mostly during dose escalation. Heart rate increased by 5 to 7 beats per minute on average, peaking around week 24 and declining afterward. Serious adverse events occurred at 4 percent in both retatrutide and placebo arms. Cutaneous hyperesthesia or skin sensitivity was reported in approximately 7 percent of retatrutide participants versus 1 percent on placebo. That early skin-sensation signal turned out to be more significant than the Phase 2 numbers suggested.

TRIUMPH-4: The First Phase 3 Readout

TRIUMPH-4 was a 68-week, randomized, placebo-controlled trial in 445 adults with obesity or overweight (BMI ≥30 or ≥27 with comorbidities) plus moderate-to-severe knee osteoarthritis, excluding type 2 diabetes. Participants were randomized 1:1:1 to retatrutide titrated to 9 mg, retatrutide titrated to 12 mg, or placebo. All received lifestyle counseling.

Mean weight loss at week 68 was 28.7 percent at the 12 mg dose, equivalent to roughly 71.2 pounds (32.3 kg). The 9 mg dose produced a smaller but still substantial reduction. Placebo participants lost a small percentage of body weight. Knee osteoarthritis pain measures and physical function improved measurably in both retatrutide arms. Cardiovascular risk markers including non-HDL cholesterol and systolic blood pressure moved in favorable directions.

Two safety findings from TRIUMPH-4 are worth highlighting.

First, dysesthesia (altered skin sensation, often described as tingling, burning, or numbness) appeared in 8.8 percent of patients on 9 mg and 20.9 percent on 12 mg, compared with 0.7 percent on placebo. This is a substantially larger signal than the cutaneous hyperesthesia rate seen in Phase 2. Events were described as mild and rarely led to discontinuation, but the magnitude was unexpected and is believed to be tied to glucagon receptor activity. The same signal appeared at a much lower rate in TRANSCEND-T2D-1 (a separate retatrutide trial in type 2 diabetes), where dysesthesia occurred in only 4.4 percent at 12 mg, suggesting the obesity-plus-OA population may be at higher risk for unclear reasons.

Second, discontinuation rates were higher than in tirzepatide Phase 3 trials. Adverse-event-driven discontinuation was 12.2 percent on 9 mg, 18.2 percent on 12 mg, and 4.0 percent on placebo. Some of those discontinuations were attributed to perceived excessive weight loss, with patients reaching BMI below 22 in some cases. Discontinuation rates were lower among participants with higher baseline BMI, where the absolute weight-loss target was larger.

Heart rate increases were consistent with Phase 2: approximately 6.7 bpm at peak, slightly higher than the 2 to 4 bpm typical of tirzepatide and semaglutide.

Detailed TRIUMPH-4 results will be presented at a scientific meeting in 2026 and published in a peer-reviewed journal. The topline disclosure is the basis for the analysis here.

The Remaining Phase 3 Pipeline

Seven additional Phase 3 readouts from the TRIUMPH program are scheduled through 2026.

TRIUMPH-1. Pivotal obesity trial in adults without diabetes. This is the registrational study that will support the obesity label and is the largest in the program.

TRIUMPH-2. Type 2 diabetes program. A separate diabetes head-to-head against semaglutide reported retatrutide superiority for A1C reduction in September 2025.

TRIUMPH-3. Obesity with comorbidities trial.

MASLD trial. Phase 3 in metabolic dysfunction-associated steatotic liver disease, building on the Phase 2 liver-fat substudy result.

Obstructive sleep apnea trial. Phase 3 in moderate-to-severe OSA with obesity. Tirzepatide already has an OSA indication; retatrutide is testing whether triple agonism produces additional benefit.

Chronic low back pain trial. Phase 3 in obesity with mechanical low back pain.

Cardiovascular outcomes trial. A long-duration cardiovascular risk reduction trial that will define whether the metabolic benefits translate into cardiac event reduction. Outcomes trials typically take three to five years to read out and are the most important data point for chronic-disease labeling.

A New Drug Application is projected for the fourth quarter of 2026 or first quarter of 2027 based on completion of the obesity and diabetes pivotal trials. FDA approval, if granted under a standard 10-month review, would arrive in late 2027.

Retatrutide activates three distinct receptors with a single molecule. Each adds a different metabolic effect on top of the next.

GLP-1 receptor activation is the part shared with semaglutide, liraglutide, and other GLP-1 analogs. It slows gastric emptying, reduces appetite, and triggers glucose-dependent insulin release from pancreatic beta cells. This is the receptor that does most of the appetite work.

GIP receptor activation is the part shared with tirzepatide. It modifies adipose-tissue insulin sensitivity, partially counteracts the gastrointestinal slowing from GLP-1 to allow higher tolerated dosing, and may directly contribute to energy expenditure through pathways in brown adipose tissue.

Glucagon receptor activation is what makes retatrutide different from anything currently approved. Glucagon is best known for raising blood sugar by stimulating hepatic glucose production. That sounds counterintuitive for a diabetes or weight-loss drug. The reason it works in this context is that glucagon also increases energy expenditure and drives hepatic lipid oxidation. When paired with strong GLP-1 activity (which suppresses the appetite that would normally compensate) and GIP activity (which preserves insulin action), glucagon's energy-expenditure contribution adds to the total weight-loss effect without the expected hyperglycemic penalty.

The receptor-binding affinity is engineered to be selective and balanced. Retatrutide has roughly equipotent activity at GIP and GLP-1 receptors and somewhat weaker but still meaningful glucagon receptor activity, calibrated to avoid the rebound glucose problem that earlier dual GLP-1/glucagon agonists encountered. Half-life is approximately six days, which supports the once-weekly dosing.

Weight Loss Outcomes

The retatrutide weight-loss curve is the steepest documented for any incretin agent.

Phase 2 (Jastreboff 2023): 24.2 percent mean weight loss at 12 mg over 48 weeks. Dose-response was clear: 7.2 percent at 1 mg, 13.9 percent at 4 mg, 17.5 percent at 8 mg, and 24.2 percent at 12 mg. Approximately 36 percent of 12 mg participants achieved 25 percent or greater weight loss, a threshold rarely reached by semaglutide or tirzepatide.

Phase 3 TRIUMPH-4: 28.7 percent mean weight loss at 12 mg over 68 weeks in obesity with knee osteoarthritis. The Phase 3 curve was steeper than Phase 2 partly because the longer trial duration allowed continued descent of the weight-loss trajectory.

Phase 3 TRANSCEND-T2D-1 (type 2 diabetes): Smaller absolute weight loss than in obesity (diabetic populations consistently lose less weight on incretin agents) but still superior to semaglutide at the doses tested. Specific numbers will be detailed at scientific congress presentation.

The pattern across trials is that retatrutide produces 4 to 6 percentage points more weight loss than tirzepatide and 10 to 15 percentage points more than semaglutide at currently labeled doses. The 7.2 mg high-dose semaglutide (STEP UP) has narrowed the semaglutide gap somewhat but has not closed it.

Cardiometabolic Outcomes

Across Phase 2 and the available Phase 3 readouts, retatrutide has produced favorable changes in cardiovascular risk markers.

Lipids. Non-HDL cholesterol, LDL, and triglycerides decreased significantly. HDL changes have been smaller and variable across trials.

Blood pressure. Systolic blood pressure decreased by approximately 5 to 10 mmHg at the higher doses, similar in magnitude to other incretin agents.

A1C. In the type 2 diabetes program, A1C reductions of approximately 2.0 percentage points at 12 mg were reported in TRANSCEND-T2D-1, exceeding semaglutide head-to-head.

Liver fat. The Phase 2 MASLD substudy reported 86 percent reduction in hepatic fat fraction at 48 weeks on the 12 mg dose, with 93 percent of participants reaching normal liver fat (below 5 percent hepatic fat fraction). This is one of the largest hepatic-fat reductions ever documented in a pharmacotherapy trial.

Glycemic effects in non-diabetics. Despite glucagon receptor activation, fasting plasma glucose did not increase in non-diabetic participants in Phase 2 or Phase 3 obesity trials. The simultaneous GLP-1 activity appears to compensate fully for the glucagon-driven hepatic glucose production.

Side Effect and Tolerability Findings

Heart rate. A sustained increase of approximately 6.7 bpm at peak, larger than the 2 to 4 bpm typical of tirzepatide and semaglutide. The mechanism is incompletely characterized. Long-term cardiovascular implications will be addressed by the cardiovascular outcomes trial.

Dysesthesia (altered skin sensation). The most distinctive signal in TRIUMPH-4. Tingling, burning, or numbness was reported in 8.8 percent at 9 mg and 20.9 percent at 12 mg, versus 0.7 percent on placebo. Events were rated mild in most cases and rarely led to discontinuation, but the magnitude was unexpected. The same signal appeared at much lower rate (4.4 percent at 12 mg) in TRANSCEND-T2D-1, suggesting the obesity-plus-OA population is at higher risk for unclear reasons. The dysesthesia is believed to relate to glucagon receptor activity at peripheral nerve sites, although the mechanism is still under investigation.

Discontinuation. Adverse-event-driven discontinuation was 12.2 percent on 9 mg and 18.2 percent on 12 mg in TRIUMPH-4, higher than the comparable rates of approximately 5 to 7 percent in tirzepatide Phase 3 trials. Some discontinuations were attributed to perceived excessive weight loss (BMI below 22 in some participants).

Body Composition

Detailed DEXA-based body composition data from the larger TRIUMPH trials has not yet been released. The Phase 2 substudy data suggested approximately 40 percent of total weight loss was fat-free mass, consistent with other incretin agents. Whether glucagon receptor activation produces more lean-mass loss than tirzepatide at equivalent endpoints is an open question that TRIUMPH-1 and TRIUMPH-3 body-composition substudies should resolve.

Off-Label and Research-Chemical Use (Caveat)

Retatrutide appears in research-chemical vendor catalogs despite not being legally available outside clinical trials. Reports from users of these products are observational, the products themselves are unverified for identity and purity, and dosing patterns vary widely. Any subjective effects reported through research-chemical use cannot be reliably attributed to retatrutide as designed and tested by Lilly. The peptscope position on this is that the only credible effects data are from the registered Phase 2 and Phase 3 trials described above.

Retatrutide is not FDA-approved for any indication. It is not eligible for compounding under FDA rules. The dosing information below is reported from registered clinical trials and is intended for informational reference, not as a personal dosing protocol.

TRIUMPH Phase 3 Titration Schedule

The Phase 3 TRIUMPH program titrates retatrutide upward over approximately 24 weeks to reach maintenance doses of 9 mg or 12 mg once weekly. The dose-escalation schedule is:

Week 1 to 4: 0.25 mg subcutaneously once weekly (starter dose, not intended for therapeutic effect; used to limit gastrointestinal adverse events).

Week 5 to 8: 0.5 mg weekly.

Week 9 to 12: 1 mg weekly.

Week 13 to 16: 2 mg weekly.

Week 17 to 20: 4 mg weekly.

Week 21 to 24: 8 mg weekly.

Week 25 onward (12 mg arm): Increase to 12 mg weekly, maintain through end of trial.

Week 25 onward (9 mg arm): Maintain at 9 mg weekly through end of trial.

The slow upward titration is driven by gastrointestinal tolerance. Direct initiation at 8 or 12 mg would produce intolerable nausea, vomiting, and diarrhea in most patients. Even with the 24-week titration, 12.2 to 18.2 percent of TRIUMPH-4 participants discontinued due to adverse events. The Phase 2 trial used a similar but somewhat compressed titration schedule.

Phase 2 Doses (Jastreboff 2023)

The Phase 2 trial tested four maintenance doses: 1 mg, 4 mg, 8 mg, and 12 mg weekly. Titration to each maintenance dose used a similar step-up schedule to Phase 3. The 8 mg and 12 mg groups were further split by fast versus slow titration speed. The slower titration arm showed better gastrointestinal tolerability without compromising weight-loss endpoints.

Pharmacokinetics

Retatrutide has a plasma half-life of approximately six days. Peak concentrations occur 24 to 48 hours after subcutaneous injection. Steady-state plasma concentrations are reached after approximately 5 weekly doses (about 5 to 6 weeks). The long half-life supports the once-weekly dosing schedule and means dose changes take approximately a month to fully take effect.

The peptide is cleared by proteolytic degradation in plasma and tissue. Renal and hepatic impairment did not produce clinically meaningful pharmacokinetic changes in published Phase 1 work, although formal labeling guidance will follow NDA submission.

Reconstitution and Administration in Clinical Trials

In TRIUMPH program clinical trials, retatrutide is supplied as a lyophilized powder by Eli Lilly to investigator sites. Reconstitution with bacteriostatic water is performed by qualified site personnel at trial-defined concentrations matched to the prescribed dose. Administration is subcutaneous injection in the abdomen, thigh, or upper arm, with site rotation.

Outside the clinical-trial setting, retatrutide is not legally available. The product is not FDA-approved, is not eligible for 503A or 503B compounding (which requires FDA approval or shortage status, neither of which applies here), and is not available through any prescription channel. Research-chemical vendors offering "retatrutide" products are operating outside the regulated supply chain. These products lack pharmaceutical-grade manufacturing controls, identity verification, and concentration consistency. The peptscope editorial position is to report clinical-trial doses for reference and to refrain from describing research-chemical reconstitution as if it were a legitimate use case.

Why No Off-Label Compounded Pathway Exists

Several other peptides on this site are available through 503A or 503B compounding pharmacies under specific FDA pathways (former approval with regulatory grandfathering, Category 1 bulks listing, or shortage status during FDA-recognized supply gaps). Retatrutide qualifies for none of these. It has never been approved. It is not on the bulks list. It has never been in shortage because it has never been on the market. Compounding pharmacies that produce retatrutide are doing so outside the regulatory framework that governs legitimate compounding. The FDA has issued warning letters to compounders producing peptides that lack appropriate regulatory pathways, and retatrutide is squarely in that category.

A few points beyond the headline TRIUMPH-4 numbers are worth attention for anyone tracking the program.

Pancreatitis risk. As with all incretin agonists, retatrutide carries theoretical and observed pancreatitis risk. Trial monitoring requires immediate discontinuation if pancreatitis is suspected. Rates appear similar to the existing GLP-1 class.

Thyroid C-cell tumor warning. Same boxed-warning structure as tirzepatide and semaglutide, based on rodent data with a different GLP-1 analog. Personal or family history of medullary thyroid carcinoma or MEN2 syndrome is an absolute contraindication.

Glucagon activity and lean mass. Glucagon receptor activation drives hepatic protein turnover. Whether retatrutide produces more lean-mass loss than tirzepatide at equivalent weight-loss endpoints is an open question that the published trial data does not yet resolve. DEXA or MRI-based body-composition substudies in TRIUMPH-1 and TRIUMPH-3 should clarify this.

Heart rate. The 6 to 7 bpm sustained increase is larger than for other incretin agonists. The long-term cardiovascular implications of sustained heart-rate increase in patients with significant weight loss are not yet established and will be addressed in the cardiovascular outcomes trial.

Dysesthesia. The Phase 3 signal was unexpected at the magnitude observed in TRIUMPH-4. Whether this represents a glucagon-receptor-mediated peripheral nerve effect or a different mechanism remains under investigation. The signal will be a focus of FDA review during NDA evaluation.

Four molecules dominate the next-generation incretin obesity space heading into 2027.

Retatrutide vs Tirzepatide

Tirzepatide is the current Phase 3 benchmark in obesity. SURMOUNT-1 reported 22.5 percent weight loss at 72 weeks on the 15 mg dose. TRIUMPH-4 reports 28.7 percent at 68 weeks on retatrutide 12 mg. The retatrutide weight-loss curve is steeper, but no head-to-head obesity trial has been completed at currently labeled doses. The side-effect profile diverges. Tirzepatide produces approximately 4 to 7 percent adverse-event discontinuation in SURMOUNT trials. Retatrutide produced 12 to 18 percent in TRIUMPH-4. The dysesthesia signal is specific to retatrutide. Heart rate increase is larger with retatrutide. The trade-off is greater weight-loss magnitude for a more challenging tolerability profile.

Retatrutide vs Semaglutide

Semaglutide is the established mass-market GLP-1 agonist. STEP-1 reported 14.9 percent weight loss at the 2.4 mg dose. STEP UP reported 20.7 percent at the new 7.2 mg dose. The TRANSCEND-T2D-1 trial directly compared retatrutide to semaglutide in type 2 diabetes and reported retatrutide superiority for both A1C reduction and weight loss. The dysesthesia signal in that trial was much smaller (4.4 percent at 12 mg) than in TRIUMPH-4, which complicates the side-effect comparison. The cardiovascular outcomes data favors semaglutide for now (20 percent MACE reduction in SELECT), but retatrutide's cardiovascular outcomes trial will read out in 2027 or 2028.

Retatrutide vs Survodutide

Survodutide is Boehringer Ingelheim's dual GLP-1/glucagon agonist. It lacks the GIP receptor activity that retatrutide carries, which is the central mechanistic difference. Phase 2 weight loss for survodutide was approximately 19 percent at 46 weeks at the high dose, intermediate between tirzepatide and retatrutide. Phase 3 is ongoing. Whether the GIP arm in retatrutide produces meaningful clinical advantage over dual agonism alone is one of the central scientific questions in the next-generation incretin space.

Regulatory Timeline

NDA submission is projected for the fourth quarter of 2026 or first quarter of 2027 based on completion of the obesity and diabetes pivotal trials (TRIUMPH-1, TRIUMPH-2, TRIUMPH-3). FDA approval, if granted under a standard 10-month review, would arrive in late 2027 or early 2028. The cardiovascular outcomes trial will read out separately and likely after initial approval, with the cardiovascular indication potentially added by label expansion in 2029 or later.

For most patients in 2026, retatrutide is not a current treatment option. The decision between semaglutide and tirzepatide remains the primary practical comparison for now.

For informational and educational purposes only. Not medical advice. Not for human consumption unless prescribed by a licensed physician for an FDA-approved indication. Consult a qualified healthcare provider before using any peptide or pharmaceutical product.